NBIX: Neurocrine Biosciences, Inc.
About
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.
Current Value
$119.361 Year Return
Current Value
$119.361 Year Return
Key Details
Market Cap
$12.06B
P/E Ratio
31.91
1Y Stock Return
8.69%
1Y Revenue Growth
25.72%
Dividend Yield
0.00%
Price to Book
4.4
Strategies that include NBIX
Stock's related to NBIX
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| OMCL | 28.98% | $1.96B | +30.61% | 0.00% |
| INCY | 26.57% | $13.59B | +32.56% | 0.00% |
| NVRI | 26.56% | $552.13M | +20.03% | 0.00% |
| OSW | 26.36% | $1.95B | +65.90% | 0.21% |
| EXEL | 26.09% | $9.83B | +62.16% | 0.00% |
| HWKN | 25.91% | $2.64B | +103.94% | 0.54% |
| NCNO | 25.86% | $4.63B | +36.50% | 0.00% |
| AZZ | 25.68% | $2.60B | +78.85% | 0.78% |
| CTS | 25.52% | $1.58B | +33.53% | 0.30% |
| CERT | 25.38% | $1.59B | -31.48% | 0.00% |
| ALNY | 25.31% | $30.22B | +43.13% | 0.00% |
| SHAK | 25.27% | $4.77B | +94.62% | 0.00% |
| ERII | 25.26% | $888.67M | -20.30% | 0.00% |
| UIS | 25.25% | $511.20M | +51.33% | 0.00% |
| FA | 25.11% | $3.04B | +17.64% | 0.00% |
| AXTA | 25.01% | $8.47B | +25.51% | 0.00% |
| ACLX | 24.35% | $4.74B | +69.19% | 0.00% |
| PDCO | 24.26% | $1.80B | -36.77% | 5.12% |
| DV | 24.21% | $3.26B | -37.48% | 0.00% |
| BHVN | 24.14% | $4.67B | +56.79% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| MTDR | -<0.01% | $7.21B | -1.21% | 1.47% |
| FAST | 0.01% | $46.74B | +35.26% | 1.92% |
| MWA | 0.02% | $3.80B | +86.48% | 1.06% |
| ARM | 0.02% | $139.85B | +126.83% | 0.00% |
| FIGS | -0.03% | $840.56M | -25.56% | 0.00% |
| LU | 0.04% | $2.01B | -33.75% | 0.00% |
| GNRC | -0.06% | $10.71B | +59.69% | 0.00% |
| MNR | 0.06% | $1.66B | -10.71% | 15.90% |
| QXO | -0.08% | $6.51B | -35.95% | 0.00% |
| TD | -0.09% | $97.59B | -9.20% | 5.39% |
| LILAK | -0.09% | $1.36B | +1.47% | 0.00% |
| HES | 0.09% | $45.06B | +1.32% | 1.24% |
| XPO | -0.11% | $16.97B | +63.79% | 0.00% |
| LILA | 0.12% | $1.37B | +2.95% | 0.00% |
| LOW | 0.14% | $147.08B | +30.90% | 1.74% |
| CATY | -0.14% | $3.63B | +39.53% | 2.69% |
| VRA | -0.15% | $142.82M | -35.29% | 0.00% |
| APEI | 0.16% | $339.36M | +232.64% | 0.00% |
| PLXS | 0.16% | $4.30B | +48.90% | 0.00% |
| KOF | 0.16% | $4.13B | -7.43% | 4.24% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| OOMA | -28.72% | $365.28M | +16.00% | 0.00% |
| BOX | -19.99% | $4.75B | +27.55% | 0.00% |
| TCTM | -18.25% | $8.10M | -42.99% | 0.00% |
| ARC | -17.36% | $146.66M | +18.95% | 5.90% |
| CHWY | -17.06% | $13.44B | +59.13% | 0.00% |
| PAC | -13.37% | $8.16B | +31.59% | 0.00% |
| HUSA | -11.90% | $16.69M | -11.56% | 0.00% |
| PBR | -11.07% | $52.88B | -8.22% | 5.68% |
| VNET | -11.06% | $954.90M | +33.82% | 0.00% |
| CRTO | -10.48% | $2.10B | +58.23% | 0.00% |
| SEG | -9.53% | $319.72M | +12.41% | 0.00% |
| LITB | -9.47% | $35.48M | -75.45% | 0.00% |
| CPSH | -9.28% | $20.70M | -40.13% | 0.00% |
| ASR | -9.23% | $7.56B | +26.22% | 0.00% |
| AME | -8.77% | $44.75B | +24.49% | 0.56% |
| GTE | -8.55% | $225.69M | -1.28% | 0.00% |
| NKE | -8.28% | $110.02B | -30.63% | 2.01% |
| CRUS | -8.24% | $5.34B | +32.92% | 0.00% |
| VET | -8.18% | $1.57B | -21.53% | 3.35% |
| QNTM | -8.13% | $9.19M | -94.36% | 0.00% |
ETF's related to NBIX
Uncorrelated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| COMT | 0.16% | $829.06M | 0.48% |
| JUCY | -0.18% | $324.29M | 0.6% |
| CSHI | -0.27% | $482.85M | 0.38% |
| FLRT | -0.38% | $401.26M | 0.6% |
| XHLF | 0.55% | $874.27M | 0.03% |
| KCCA | 0.61% | $220.51M | 0.87% |
| DFSD | 0.91% | $3.63B | 0.16% |
| FMF | 1.04% | $244.61M | 0.95% |
| GSG | -1.14% | $914.42M | 0.75% |
| DBE | -1.21% | $50.13M | 0.77% |
| FLMX | 1.32% | $91.21M | 0.19% |
| YEAR | 1.39% | $1.13B | 0.25% |
| XONE | 1.45% | $548.88M | 0.03% |
| MINT | -1.47% | $11.62B | 0.35% |
| AGZD | 1.56% | $142.76M | 0.23% |
| HYEM | 1.68% | $408.28M | 0.4% |
| UNG | 1.69% | $908.80M | 1.06% |
| SHV | -1.79% | $18.13B | 0.15% |
| TDTT | 1.81% | $1.84B | 0.18% |
| IBHD | 1.88% | $327.80M | 0.35% |
Inversely Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| VIXY | -17.07% | $195.31M | 0.85% |
| TAIL | -12.01% | $67.98M | 0.59% |
| BTAL | -10.96% | $388.04M | 1.43% |
| DBA | -8.26% | $755.88M | 0.93% |
| USDU | -6.40% | $201.97M | 0.5% |
| FLMI | -6.31% | $356.19M | 0.3% |
| GBIL | -6.24% | $5.60B | 0.12% |
| TPMN | -6.19% | $40.60M | 0.65% |
| FLDR | -6.15% | $595.01M | 0.15% |
| UUP | -6.08% | $309.25M | 0.77% |
| IVOL | -5.88% | $548.70M | 1.02% |
| JBBB | -5.50% | $1.26B | 0.49% |
| HYMU | -5.46% | $232.71M | 0.35% |
| BOXX | -4.94% | $4.43B | 0.1949% |
| EQLS | -4.91% | $76.08M | 1% |
| USCI | -4.82% | $185.47M | 1.07% |
| HDRO | -4.66% | $164.26M | 0.3% |
| BSJO | -4.55% | $467.93M | 0.43% |
| CANE | -4.54% | $17.72M | 0.29% |
| WEAT | -4.51% | $120.27M | 0.28% |
News
SeekingAlpha
Following underperformance in Q2 2024, the Franklin Biotechnology Discovery Fund returned to strength in Q3 2024. Click here to read the full commentary.
SeekingAlpha
Voyager Therapeutics' promising anti-tau Alzheimerâs therapy faces long timelines. See why VYGR stock is rated Hold but remains a long-term opportunity.
SeekingAlpha
Harding Loevner Global Small Companies Equity composite advanced 8%, gross, during Q3 2024, trailing the 8.9% gain in the benchmark Index. Click here to read more.
Yahoo
Over the last 7 days, the United States market has risen 5.7%, contributing to a remarkable 37% increase over the past year, with earnings forecasted to grow by 16% annually. In this dynamic environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on these favorable market conditions.
SeekingAlpha
Baird Small/Mid Cap Growth portfolio increased +6.9% in 3Q, net of fees, compared to the +7.0% increase in our primary benchmark, the Russell 2500 Growth Index.
SeekingAlpha
AbbVie's emraclidine setback in phase 2 trials impacts neuroscience pipeline, benefitting Bristol Myers Squibb's Cobenfy in muscarinic drug class. Learn more on ABBV stock here.
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.